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ABSTRACT.
Purpose: To evaluate the long-term efficacy and safety of two minimally invasive
glaucoma surgery implants with a subconjunctival drainage approach: the
XEN45 Gel Stent (Xen) implant and the PRESERFLOTM MicroShunt
(MicroShunt).
Methods: Retrospective comparative case series of primary open-angle glau-
coma (POAG) patients with at least 6 months of follow-up after a MicroShunt
or Xen implantation augmented with mitomycin C.
Results: Forty-one eyes of 31 patients underwent Xen implantation, and 41 eyes
of 33 patients, MicroShunt implantation. Baseline characteristics were similar,
except for more combined surgeries with phacoemulsification in the Xen group
(37% vs. 2%). Mean baseline IOP  standard deviation dropped from
19.2  4.4 to 13.8  3.8 mmHg (n = 26) in the Xen group and from
20.1  5.0 to 12.1  3.5 (n = 14) in the MicroShunt group at 24 months of
follow-up (p = 0.19, t-test). The number of IOP-lowering medications dropped
from 2.5  1.4 to 0.9  1.2 in the Xen group and from 2.3  1.5 to 0.7  1.1
in the MicroShunt group. The probability of qualified success was 73% and 79%
at 24 months of follow-up for the Xen and MicroShunt groups, respectively.
Postoperative complications were usually mild and self-limiting. The number of
bleb needling and secondary glaucoma surgery procedures was similar in both
groups; however, in the Xen group more additional MicroPulse transscleral
cyclophotocoagulation procedures were performed.
Conclusion: Xen Gel Stent and PreserFlo MicroShunt implantations achieved
comparable results in POAG eyes in terms of IOP-lowering and surgical
success, with a similar high safety profile.
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Introduction
In recent years, surgical options for the
treatment of glaucoma have increased
with the introduction ofminimally inva-
sive glaucoma surgery (MIGS). These
surgeries aim to reduce intraocular pres-
sure (IOP) in a safer and less traumatic
manner in comparison with traditional
glaucomafiltering surgery (Francis et al.
2011; Caprioli et al. 2015).
The mechanism of action differs
among MIGS. The XEN 45 Gel Stent
(Allergan Inc., Dublin, Ireland) (Xen)
(Lewis 2014) and the PRESERFLOTM
MicroShunt (Santen, Osaka, Japan)
(MicroShunt) (Pinchuk et al. 2017) drain
aqueous humour into the subconjuncti-
val space, similar to the gold standard,
trabeculectomy (Cairns 1968). The Xen,
usually implanted via an ab interno
approach with an injector, is a 6-mm-
longandflexible tubewitha45-µmlumen
made of cross-linked porcine gelatine
(Lewis 2014). The 8.5-mm-long Micro-
Shunt is made of a stable and flexible
polymer ‘SIBS’ (poly[styrene-block-
isobutylene-block-styrene]), which is
already used for long-term implantation
in the body in cardiac stents (Pinchuk
et al. 2008). It has a lumen diameter of
70 µmand is implanted via an ab externo
approach (Pinchuk et al. 2017). The
design of both tubes is based on the
Hagen–Poiseuille equation, limiting early
postoperative hypotony (Sheybani et al.
2015). To reduce the risk of fibrosis, both
procedures are augmented with intraop-




To the best of our knowledge, there
is currently no report comparing these
two techniques. In this study, we com-
pare both the effectiveness and safety
of Xen versus MicroShunt implanta-
tions after a follow-up of 2 years.
Methods
Study design
This is a retrospective study comparing
the effectiveness, safety and success rate
of Xen and MicroShunt implantations
augmented with MMC in patients with
primary open-angle glaucoma (POAG).
The study protocol adhered to the
tenets of the Declaration of Helsinki
and was conducted after approval by
the local ethics committee. All surgeries
were performed by experienced glau-
coma surgeons who were proficient in
both procedures under study.
Patients and assessments
We included all Xen and MicroShunt
implantations consecutively performed
in patients with POAG between
November 2014 and June 2019 at the
University Eye Clinic, Maastricht, the
Netherlands. Patients were eligible for
surgery if they were inadequately con-
trolled on maximum tolerated medical
therapy and/or had progression of
visual field loss. Patients were excluded
from the analysis if they had less than
6 months of follow-up.
Baseline data collected from the
patient history included age, sex, race,
systemic and ocular history, the treated
eye, glaucoma severity, IOP and IOP-
lowering medication use. Glaucoma
severity was defined using the
Hodapp–Parrish–Anderson (H-P-A)
classification (Hodapp et al. 1993). Post-
operative evaluations were documented
on day 1, week 1 and months 1, 3, 6, 12,
18 and 24 using the acceptable time
windows proposed by the World Glau-
coma Association (WGA) guidelines
(Shaaraway et al. 2009). At each time-
point, slit-lamp examination, medica-
tion use, IOP assessment by Goldmann
applanation tonometry, complications
and additional interventions were
extracted from clinical records.
Ab interno Xen Gel Stent implantation
The Xen implantation was performed
under sub-Tenon’s (90%), retrobulbar
or topical anaesthesia using an ab
interno approach. After anaesthesia,
reference points were marked in the
superonasal conjunctiva, 3 mm from
the limbus. Prior to the procedure,
0.1 ml of a 0.2 mg/ml MMC solution
was injected in the nasal superior
quadrant, under Tenon’s capsule, and
massaged over the area of the antici-
pated insertion site. A main 1.2-mm
corneal paracentesis incision was made
in the inferotemporal quadrant, and
the anterior chamber (AC) was filled
with an Ophthalmic viscosurgical
device (ProVisc, Alcon Laboratories
Inc., Fort Worth, TX, USA) (OVD).
The injector was directed through the
incision across the AC towards the
superonasal quadrant and placed
through the sclera in the subconjuncti-
val space with 1–2 mm left in the AC.
Placement was confirmed immediately
after the implantation using a gonio-
lens. If the surgery was combined with
cataract extraction, a regular pha-
coemulsification was performed after
MMC injection. After instilment of a
miotic drug (MIOSTATTM, Alcon Lab-
oratories Inc.), the XEN stent was
implanted. In all cases, the OVD was
carefully removed at the end of the
procedure, and tube flow checked.
Ab externo MicroShunt procedure
All MicroShunt implantations were
performed under sub-Tenon’s anaes-
thesia. A fornix-based conjunctival flap
was created in the superonasal or
superotemporal quadrant. A deep
sub-Tenon’s pocket was formed, and
wet cautery was applied to the scleral
vessels in the intended area of place-
ment. Mitomycin C (MMC) (0.2 mg/
ml) was applied to the scleral surface
using several in MMC-soaked Lasik
shields placed under the conjunctival/
Tenon’s flap for 3 min. After the
shields were removed, the area was
thoroughly rinsed with balanced salt
solution (BSS, Alcon Laboratories,
Inc.). The sclera was marked 3 mm
from the limbus. A scleral pocket was
made using a 1-mm triangular knife,
after which in this pocket a 25-gauge
needle was introduced to create a
needle track into the AC. The Micro-
Shunt was inserted into the AC
through the needle track, tucking the
fin of the device tightly into the pocket.
After checking for flow, Tenon’s cap-
sule and conjunctiva were sutured in a
watertight manner. If the implantation
was combined with cataract extraction,
phacoemulsification was performed
after the irrigation of MMC. In a
combined procedure, the OVD was
carefully removed after phacoemulsifi-
cation, after which a miotic drug
(MIOSTATTM, Alcon Laboratories,
Inc.) was instilled and the eye pressur-
ized with BSS, before placing the
MicroShunt.
Postoperative management
Both procedures were directly followed
by a prophylactic intracameral antibi-
otic injection [cefuroxime, (Aprokam,
Laboratoires Thea, Clermont-Ferrand,
France)] and an anti-inflammatory sub-
conjunctival steroid (dexamethasone)
injection in the operating room. All
IOP-lowering medications were discon-
tinued immediately after the surgery.
Postoperatively, topical unpreserved
antibiotic prophylaxis [ofloxacin, (Tra-
floxal, Bausch & Lomb Pharma,
Bridgewater, NJ, USA)] was prescribed
four times daily during a period of two
weeks. Topical anti-inflammatory ther-
apy with unpreserved steroids (dexam-
ethasone 0.1%) started at four to six
times a day and was tapered off slowly
over a period of several months accord-
ing to bleb formation and wound heal-
ing. Intraocular pressure (IOP) was
assessed at every postoperative visit.
Postoperative IOP-lowering medication
was added in case of raised IOP, and
bleb needling or interventions were per-
formed at the discretion of the treating
ophthalmologist.
Bleb needling and revision were per-
formed in the operating room. During
needling, a 30-G needle was introduced
into the bleb to release adhesions of the
Tenon’s capsule, followed by injection
of an anti-fibrotic agent 5-Fluorouracil
(5-FU) (0.1 ml of 50 mg/ml) or MMC
(0.1 ml of 0.2 mg/ml). Revisions were
performed by opening the conjunctival
wound area and removing tube adhe-
sions. In cases with severe bleb fibrosis,
a tenonectomy was performed and, if
considered necessary, the procedure
was augmented with the application of
MMC or an Ologen implant (Aeon
Astron Europe, the Netherlands).
Outcome measurements
The primary outcome was the IOP
after 12 and 24 months of follow-up.
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Secondary parameters included the
number of postoperative IOP-lowering
medications, adverse events, additional
glaucoma interventions and surgical
success rates. Surgical success was
defined as a postoperative
IOP ≤ 18 mmHg at 2 consecutive fol-
low-up visits after 3 months of follow-
up. If success was achieved without
medication, additional glaucoma sur-
gery or other glaucoma therapy, it was
considered a complete success. Quali-
fied success was obtained if target IOP
was achieved without any additional
glaucoma interventions, with or with-
out IOP-lowering medication. Bleb
needling or revision was not considered
a failure. The time to failure was
defined as the time to reoperation or
the first visit of 2 consecutive visits
after 3 months in which the patient had
an IOP > 18 mmHg.
Cases that required an additional
glaucoma intervention were only
included in the postoperative analysis
up to the moment of the decision to
intervene.
Statistical analysis
Data were collected from the electronic
patient records, and statistical analysis
was performed using SPSS Statistics
version 26 (IBM Inc., Armonk, NY,
USA).
Baseline characteristics and study
outcomes were compared using inde-
pendent-samples Student’s t-test for
continuous variables and chi-square
test and Fisher’s exact test, as needed,
for categorical variables.
An independent-samples Student’s t-
test was used for the evaluation of IOP
from baseline up to 24 months between
the Xen and MicroShunt groups.
Additionally, the probability of suc-
cess was assessed using Kaplan–Meier
survival curves. Success probabilities
between the groups were compared
using log-rank (Mantel–Cox) test. All
tests in our analysis were 2-sided, and a




A total of 82 implantations were
included in the analysis. Forty-one eyes
in 31 patients received a Xen implan-
tation, and 41 eyes in 33 patients
received a MicroShunt implantation.
The main baseline clinical and demo-
graphic characteristics are presented in
Table 1. No significant differences were
observed in the baseline characteristics
between the Xen group and the Micro-
Shunt group. Disease severity was
evenly distributed between the groups,
with most patients having moderate
glaucomatous damage.
The Xen implantation was per-
formed in combination with cataract
extraction in 15 (37%) cases versus 1
(2%) case in the MicroShunt group
(p < 0.001). Mean follow-up duration
after the primary surgery was 22.4 and
18.9 months in the Xen and Micro-
Shunt groups, respectively.
Intraocular pressure
IOP measurements for the Xen and
MicroShunt groups are reported in
Table 2. At baseline, mean IOP was
similar between the groups (p = 0.39).
Postoperatively, patients were censored
from the time-point and additional
incisional glaucoma surgery was per-
formed. Mean IOP in the Xen group
dropped from 19.2  4.4 mmHg at
baseline to 13.3  2.9 mmHg (31%)
at 12 months and 13.8  3.8 mmHg
(28%) at 24 months of follow-up. In
patients who received a MicroShunt,
mean IOP decreased from
20.1  5.0 mmHg at baseline to
12.1  3.5 mmHg (40%) at 12 months
and 12.1  3.5 mmHg (39%) at
24 months of follow-up. We found
lower IOP values in the MicroShunt
group at all time-points; however, this
difference was only statistically signif-
icant at month 1 and month 3 (Fig. 1).
Medication
The mean number of IOP-lowering
medications dropped from 2.5  1.4
and 2.3  1.5 at baseline to 0.8  1.2
and 0.6  1.0 at 12 months and
0.9  1.2 and 0.7  1.1 at 24 months
of follow-up in the Xen and Micro-
Shunt groups, respectively. At
24 months, 62% (16/26) versus 64%
(9/14) of patients were free of IOP-
lowering medication in the Xen group
versus the MicroShunt group, respec-
tively (p = 0.86). Mean IOP at
24 months in the medication-free
patients was 13.4  3.7 mmHg in the
Xen group and 11.6  4.2 mmHg in
the MicroShunt group (p = 0.26).
None of the patients used oral aceta-
zolamide in either of the groups at two
years of follow-up.
Surgical success rates
Kaplan–Meier survival curves for sur-
gical success are shown in Fig. 2. The
Table 1. Baseline demographics and clinical characteristics of the study population
Xen (n = 41) MicroShunt (n = 41) p-value
Study eye, OD, no. (%) 21 (51%) 21 (51 %) 1.00
Mean age  SD, yrs 69  8 66  9 0.13
Gender, male, no. (%) 20 (49%) 21 (51%) 0.83
Race, Caucasian, no. (%) 41 (100%) 41 (100%) 1.00
Mean central corneal thickness  SD, µm 540  35 531  40 0.36
Mean IOP  SD, mmHg 19.2  4.4 20.1  5.0 0.39
Mean no. of IOP-lowering medications  SD 2.5  1.4 2.3  1.5 0.65
Number of IOP-lowering medications, no (%)
0 4 (10%) 6 (15%) 0.73
1 9 (22%) 7 (17%)
2 4 (10%) 8 (20%)
3 12 (29%) 8 (20%)
4 11 (27%) 11 (27%)
5 1 (2%) 1 (2%)
Use of oral acetazolamide, no. (%) 7 (17%) 5 (12%) 0.53
Glaucoma severity, no. (%)
Mild up to 6.00 dB 14 (34%) 11 (27%) 0.76
Moderate 6.01 dB up to 12.00 dB 14 (34%) 15 (37%)
Advanced 12.01 dB or worse 12 (29%) 14 (34%)
Missing 1 (2%) 1 (2%)
History of phacoemulsification 10 (24%) 18 (44%) 0.06
History of laser trabeculoplasty 15 (37%) 19 (46%) 0.37
Comparisons between treatment groups were performed using the 2-sided Student’s t-test for
continuous variables and the chi-square test for categorical variables.
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probability of complete success was
46% and 58% at 12 months and 34%
and 49% at 24 months of follow-up
with a mean time to failure (95% CI) of
14.0 (11.3–16.8) and 16.6 (13.7–19.4)
months for Xen and MicroShunt
implantations, respectively (p = 0.21).
The probability of qualified success
was 78% and 79% at 12 months and
73% and 79% at 24 months of follow-
up with a mean time to failure (95%-
CI) of 20.0 (17.8–22.2) and 20.2 (17.9–
22.6) months for the Xen and Micro-
Shunt groups, respectively (p = 0.68).
Postoperative interventions
Table 3 lists the postoperative inter-
ventions. Eight eyes (20%) of patients
in the Xen group and 2 (5%) eyes in
patients in the MicroShunt group
underwent bleb needling (p = 0.09). In
both groups, two eyes (5%) underwent
bleb revision (p = 1.00). The median
(range) follow-up time between the
surgery and the first revision or need-
ling was 2.3 (0.8–6.0) months in the
Xen group and 3.0 (2.1–5.1) months in
the MicroShunt group. Another post-
operative intervention that was per-
formed was a MicroPulse transscleral
cyclophotocoagulation (IRIDEX Cor-
poration, Mountain View, CA, USA)
(MP-TSCPC) procedure in 8 (20%)
cases of the Xen group and in 1 case in
the MicroShunt group (p = 0.029).
One eye in each group underwent a
phacoemulsification combined with a
trabecular micro-bypass stent proce-
dure (iStent, Glaukos, San Clemente,
CA, USA) (phaco-iStent). Three (7%)
cases after Xen implantation and 6
(15%) cases after MicroShunt implan-
tation failed and underwent additional
glaucoma filtration surgery (p = 0.48).
The median (range) follow-up time
between the surgery and the additional
glaucoma filtration surgery was 4.9
(0.7–6.0) months in the Xen group
versus 7.0 (1.1–14.7) months in the
MicroShunt group. In both the Xen
and MicroShunt groups, one case
required operative adjustment of the
stent’s placement.
Postoperative complications
Regarding the safety profile, a com-
parison of postoperative complications
is shown in Table 4.
Early self-limiting hyphema was
commonly reported in both groups.
To evaluate hypotony, we used the
Table 2. Mean IOP and medication use for patients at baseline and at time-points during follow-up after Xen and MicroShunt implantations
Xen
MicroShunt
p-valueCombined Stand-alone All All
Baseline
IOP (mmHg) 18.4  3.3 19.6  4.9 19.2  4.4 20.1  5.0 0.39
no. of medications 2.1  1.5 2.7  1.3 2.5  1.4 2.3  1.5
n 15 26 41 41
Day 1
IOP (mmHg) 11.1  4.2 7.5  3.6* 8.8  4.1 7.9  4.0 0.34
no. of medications 0.1  0.3 0.1  0.4 0.1  0.3 0.1  0.4
n 14 26 40 41
Week 1
IOP (mmHg) 10.6  3.3 9.5  5.7 9.9  4.9 8.7  4.1 0.21
no. of medications 0.2  0.6 0.0  0.0 0.1 0.4 0.0  0.2
n 14 24 38 41
Month 1
IOP (mmHg) 15.0  6.2 12.0  6.4 13.1  6.4 10.3  3.2 0.019
no. of medications 0.3  0.7 0.2  0.7 0.2  0.7 0.0  0.0
n 14 24 38 40
Month 3
IOP (mmHg) 13.8  3.6 13.8  5.3 13.8  4.6 10.9  2.8 0.002
no. of medications 0.5  0.9 0.6  1.1 0.5  1.0 0.2  0.5
n 14 23 37 38
Month 6
IOP (mmHg) 15.5  5.7 14.0  4.3 14.5  4.8 12.5  4.2 0.07
no. of medications 0.3  0.6 0.8  1.2 0.6  1.0 0.2  0.5
n 13 22 35 34
Month 12
IOP (mmHg) 14.4  3.4 12.7  2.5 13.3  2.9 12.1  3.5 0.17
no. of medications 0.5  1.0 1.0  1.2 0.8  1.2 0.6  1.0
n 11 19 30 28
Month 18
IOP (mmHg) 14.0  2.9 12.6  1.8 13.2  2.3 12.5  3.3 0.46
no. of medications 0.7  1.2 1.5  1.3 1.2  1.3 0.6  0.9
n 10 16 26 16
Month 24
IOP (mmHg) 12.5  1.7 14.6  4.6 13.8  3.8 12.1  3.5 0.19
no. of medications 0.5  1.1 1.1  1.3 0.9  1.2 0.7  1.1
n 10 16 26 14
IOP = intraocular pressure. Shown is mean  standard deviation. Patients were censored from analysis when they received an additional
intervention. Comparisons between treatment groups were performed using the 2-sided Student t-test. *p-value < 0.05.
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numeric definition of an
IOP ≤ 5 mmHg after surgery sug-
gested by the World Glaucoma Asso-
ciation guidelines (Shaaraway et al.
2009). A single measurement of hypot-
ony at day 1 and/or week 1 was seen in
10 (24%) of the patients in the Xen
group and 16 (39%) of the patients in
the MicroShunt group (p = 0.15). By
month 1, hypotony had resolved in all
cases in the MicroShunt group; how-
ever, it persisted in three cases of the
Xen group. Due to hypotony, two
patients in the Xen group and one
patient in the MicroShunt group
needed reformation of the AC in the
first postoperative week. In both
groups, one case of (nonkissing) chor-
oidal detachment was observed, requir-
ing reformation of the AC after the
Xen implantation and resolving spon-
taneously for the case in the Micro-
Shunt group.
In the Xen group, 6 (15%) cases of
curling of the stent were described. In
one Xen patient, the stent migrated
into the direction of the AC, requiring
repositioning in the operating room.
No cases of device exposure or migra-
tion were seen in the MicroShunt
group. In one case, the iris occluded
the lumen of the tube and repositioning
was performed in the operating room.
Discussion
In this study, we compared the out-
come on efficacy and safety of two
minimally invasive glaucoma implants
for subconjunctival drainage (the Xen
and MicroShunt implants, augmented
with MMC), in patients with POAG.
Both procedures were found to be
effective in lowering IOP and reducing
the number of postoperative IOP-low-
ering medications. Our results suggest
that Xen and MicroShunt implants
may have similar IOP-lowering poten-
tial and surgical effectiveness in POAG
patients. Overall, 73% of eyes with Xen
implantation and 79% of the Micro-
Shunt implantations showed qualified
success (i.e. an IOP value ≤ 18 mmHg
without additional glaucoma interven-
tion) after 24 months of follow-up. In
both groups, mean IOP dropped to the
low teens at 12 months and 24 months
of follow-up. The mean number of
IOP-lowering medications was also
reduced in both groups, with more
than half of the patients completely off
medications after 24 months.
We found no differences in the
number of bleb needling and additional
glaucoma filtration surgery rates. How-
ever, MP-TSCPC was performed less
often in the MicroShunt group.
We were challenged by how to
interpret the additional MP-TSCPC
and phaco-iStent procedures per-
formed during follow-up. These new
procedures are less invasive in compar-
ison with conventional incisional surg-
eries but could have a significant
moderating effect on outcomes. Per-
forming a sensitivity analysis showed
no differences in outcomes in our
cohort. However, as the literature sug-
gests a significant IOP reduction up to
30–40% after both MP-TSCPC and
phaco-iStent procedures we decided to
include cases in the analysis only up to
these interventions (Neuhann 2015;
Davids et al. 2018; Macher et al.
2018; de Crom et al. 2020).
Previously published prospective
and retrospective studies showed that
Xen implantation in patients with
open-angle glaucoma is a safe and
effective method with a mean IOP in
Fig. 1. Mean intraocular pressure and medication use during follow-up after Xen and MicroShunt implantations in patients with primary open-angle
glaucoma. Error bars represent the 95% confidence interval.
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the mid-teens after one or two years of
follow-up (Fea et al. 2017; Mansouri
et al. 2018a; Tan et al. 2018; Widder
et al., 2018; Gillmann et al. 2019;
Heidinger et al. 2019; Kalina et al.
2019; Reitsamer et al., 2019; Smith
et al. 2019). In a large prospective study
of 202 Xen implantations in POAG
patients, Reitsamer et al., (2019)
showed an overall mean IOP of
14.9  4.5 and 15.2  4.2 mmHg at
12 and 24 months postoperatively.
Outcomes in our current study are at
least as favourable as in this prior
study.
Currently, limited evidence is avail-
able on the MicroShunt, including and
restricted to industry-initiated trials. A
pioneering study showed a mean IOP
of 11.9  3.7, two years after Micro-
Shunt implantation augmented with
0.4 mg/ml MMC (Batlle et al. 2016).
However, preliminary results from an
international multicenter prospective
trial presented at the World Glaucoma
Congress showed a mean IOP of
14.8  5.0 at two years of follow-up
(Garcıa-Feijoo et al. 2019). In this
latter study, 0.2 mg/ml MMC was
used. Our present results show a more
favourable outcome with this lower
concentration of MMC. More evidence
is needed on the desired concentration
of MMC.
Hypotony was quite common in
both groups within the first postoper-
ative month. However, the incidence of
hypotony-related complications was
low. In a cohort following 300 tra-
beculectomy patients, numerical hypot-
ony of ≤ 5 mmHg was seen in 47% at
any time during follow-up and persis-
tent hypotony in two consecutive visits
after 1 month in 11% of patients
(Abbas et al. 2018). Our cohort shows
lower rates of hypotony with both
minimally invasive glaucoma implants
in comparison with this study on tra-
beculectomy.
Even though the two implants have
a similar drainage approach, they differ
in a few aspects. Firstly, the Xen
implant is implanted via an ab interno
approach, without opening the con-
junctiva, whereas the MicroShunt is
implanted via an ab externo approach,
quite similar to trabeculectomy. Sec-
ondly, the two implants use a different
method of administration and amount
of MMC. It is known that both the
concentration and duration of MMC
exposure have an effect on the surgical
success of glaucoma filtration surgery
(Al Habash et al. 2015). Thirdly, the
material and design of the two implants
differ, which may possibly have differ-
ent effects on biocompatibility, foreign-
body reaction and migration after
implantation. Widder et al. (2019)
recently published a case report of
stent degradation after Xen implanta-
tion. The long-term effect of these
materials in glaucoma patients is yet
to be established.
The current study has several limi-
tations, mainly relating to its retrospec-
tive nature. Therefore, results should
be interpreted in the light of this
design. Outcomes are collected via
routine clinical practice and not via a
reporting protocol. Nevertheless, col-
lecting data from clinical routine gives
a realistic representation of current
clinical practice. Because all patients
were Caucasians, this study cannot
offer conclusions on effectiveness and
safety for other ethnic populations. In
addition, although the surgeons were
all experienced glaucoma surgeons, a
learning curve may have influenced the
results, as these are both new tech-
niques. The effect of needling and
revision had to be studied, and in
several cases, this was not attempted
and we directly opted for further inci-
sional glaucoma surgery for safety
reasons. We are aware that analysis of
both eyes of the same patient has the
potential to lead to (selection) bias.
However, a post hoc sub-analysis of
(A)
(B)
Fig. 2. Kaplan–Meier survival curve showing the probability of success after Xen and
MicroShunt implantations. (A) Complete success is defined as an IOP ≤ 18 mmHg without
medication or additional glaucoma interventions. (B) Qualified success is defined as an
IOP ≤ 18 mmHg without additional glaucoma interventions, with or without medication.
6
Acta Ophthalmologica 2020
the mean IOP during follow-up includ-
ing first eyes only showed similar
results in both groups. We have chosen
to include both eyes as the use of only
one eye per individual would lead to
loss of information, without changing
the results of our analyses.
The rate of patients lost to follow-up
was considerable. This can be
explained by the retrospective study
design. Five patients returned to their
referring ophthalmologist after a suc-
cessful treatment.
Patients who received secondary
glaucoma interventions were only
included in the analysis up to the
moment of the decision to intervene.
Although this may bias the results in
favour of the MIGS procedures, we
cannot present the results in a different
way, as the IOP after an additional
intervention no longer reflects the out-
come of the initial Xen or MicroShunt
procedure.
A treatment was selected on the
basis of individual patient
characteristics and was not randomly
assigned. A Xen implantation was
more often performed in combination
with cataract extraction. The effect of a
combined surgery on the efficacy of the
filtration surgery also remains unclear.
Studies comparing the efficacy of Xen
implantation with and without cataract
extraction found similar outcomes in
both groups (Karimi et al. 2018; Man-
souri et al. 2018b; Marcos Parra et al.,
2019). It may therefore be assumed that
the combined procedure had no rele-
vant influence on the results of the
present comparison study. Performing
a sensitivity analysis comparing Xen
and MicroShunt implantations as a
stand-alone procedure versus a com-
bined procedure showed no statistical
difference except for a significant lower
IOP at day 1 postoperative in favour of
the stand-alone procedure (Table 2).
Further evidence on the outcome of
combination surgery with the Micro-
Shunt has to be awaited. Finally, the
number of cases in our analysis might
have been too low to detect statistical
differences between the two implants.
A larger cohort and longer follow-up
will give further insights into the pros
and cons of these two new devices.
In conclusion, both the XEN45Gel
Stent and the PRESERFLOTM Micro-
Shunt demonstrated safe and effective
lowering of IOP and the need for IOP-
lowering medications, with similar suc-
cess rates after 2 years. Our cohort
showed a higher number of MP-
TSCPC procedures in the Xen group.
Selecting a minimally invasive device
should take into consideration IOP
target, the patient’s compliance with
IOP-lowering medications, optimal
bleb management and the surgeon’s
personal preferences. Further prospec-
tive head-to-head trials and cost-effec-
tiveness studies are essential to
determine the place of these new
devices for the surgical treatment of
glaucoma.
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